Newtyn Management, LLC Cyteir Therapeutics, Inc. Transaction History

Newtyn Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.84 - $3.13 $1.48 Million - $1.63 Million	521,056 Added 20.84%	3,021,500 $9.19 Million
Q3 2023 Nov 14, 2023	BUY	$2.71 - $2.84 $3.1 Million - $3.24 Million	1,142,395 Added 84.12%	2,500,444 $7.1 Million
Q2 2023 Aug 14, 2023	BUY	$1.74 - $2.6 $704,877 - $1.05 Million	405,102 Added 42.51%	1,358,049 $3.53 Million
Q1 2023 May 15, 2023	SELL	$1.47 - $1.84 $98,567 - $123,377	-67,053 Reduced 6.57%	952,947 $1.73 Million
Q4 2022 Feb 14, 2023	BUY	$1.18 - $1.76 $431,747 - $643,962	365,888 Added 55.94%	1,020,000 $1.68 Million

Q3 2022 Nov 14, 2022	BUY	$1.99 - $4.05 $95,249 - $193,849	47,864 Added 7.9%	654,112 $1.26 Million
Q2 2022 Aug 15, 2022	BUY	$1.62 - $4.4 $982,121 - $2.67 Million	606,248 New	606,248 $1.81 Million

6.18M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Newtyn Management, LLC with notifications on news.